Hostname: page-component-669899f699-vbsjw Total loading time: 0 Render date: 2025-04-26T19:53:30.648Z Has data issue: false hasContentIssue false
  • English
  • Français

Serotonin, personality and borderline personality disorder

Published online by Cambridge University Press:  24 June 2014

M. Hansenne ,
W. Pitchot  and
M. Ansseau
M. Hansenne*
Affiliation:
University of Liège, Department of Psychiatry, Liège, Belgium
W. Pitchot
Affiliation:
University of Liège, Department of Psychiatry, Liège, Belgium
M. Ansseau
Affiliation:
University of Liège, Department of Psychiatry, Liège, Belgium
*
University of Liège, Department of Psychiatry, CHU Sart Tilman (B35), B-4000 Liège, Belgium. Tel: 00 32 4 3667960; Fax: 00 32 4 3667283; E-mail: Michel.Hansenne@ulg.ac.be
Get access Rights & Permissions [Opens in a new window]

Abstract

Serotonin is one of the neurotransmitters implicated in normal personality. Many psychobiological models of personality include some dimensions related to serotonin. For instance, the harm avoidance dimension of the biosocial model developed by Cloninger is related to serotonergic activity. Higher scores on the harm avoidance dimension should theoretically reflect increased serotonergic activity. However, correlation studies related serotonin activity to harm avoidance dimension have not yielded consistent findings. These controversial results are probably related to the complexity of the neurotransmitter systems, and the different assessment techniques used in these studies. Finally, recent genetic studies have examined the association between personality dimensions and serotonergic receptor polymorphisms with mixed results. Serotonin is not only related to some dimensions of normal personality. Several psychopathological disorders are associated with serotonergic dysfunction. More particularly, borderline personality disorder (BPD) can be defined by many of the symptoms associated with serotonergic dysregulation, including affective lability, suicidal behaviours, impulsivity and loss of impulse control. Indeed, several reports have demonstrated the efficacy of selective serotonin re-uptake drugs in treating the depressive and impulsive symptoms of patients with BPD. Moreover, some challenge studies have reported a lower serotonergic activity in BPD. Because these challenges are not specific, we have assessed the serotonergic activity in BPD with the flesinoxan challenge. Preliminary results showed that the prolactine responses to flesinoxan were significantly lower in BPD patients compared to those observed in controls.

Keywords

serotoninpersonalityborderline personality disorder
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 14 , Issue 2 , April 2002 , pp. 66 - 70
Copyright
Copyright © Acta Neuropsychiatrica 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Zuckerman, M.An alternative five-factor model for personality. In: Halverson, CF Jr, Kohnstamm, GE, Martin, KP, eds. The developing structure of temperament and personality from infancy to adulthood. Hillsdale: LEA Publishers, 1994: 53–68. Google Scholar
Cloninger, CR.A unified biosocial theory of personality and its role in the development of anxiety states. Psychiatr Dev 1986;3: 167–226. Google Scholar
Cloninger, CR, Svrakic, DM, Przybeck, TR.A psychobiological model of temperament and character. Arch Gen Psychiatry 1993;50: 975–990.CrossRefGoogle Scholar
Cloninger, CR, Przybeck, TR, Svrakic, DM, Wetzel, RD. The temperament and character inventory (TCI): a guide to its development and use. St Louis, Missouri: Center for Psychobiology of Personality, Washington University, 1994.Google Scholar
Coccaro, E, Siever, LS, Klar, HMet al. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behaviour. Arch Gen Psychiatry 1989;46: 587–599.CrossRefGoogle Scholar
New, AS, Tresman, RL, Mitropoulou, Vet al. Serotonin function and self-injurious behaviour in personality disorder patients. Psychiatr Res 1997;69: 17–26. CrossRefGoogle Scholar
Pfohl, B, Black, D, Noyes, R, Kelley, M, Blum, N.A test of the tridimensional personality theory: Association with diagnosis and platelet imipramine binding in obsessive-compulsive disorder. Biol Psychiatry 1990;28: 41–46.CrossRefGoogle ScholarPubMed
Waller, DA, Gullion, CM, Petty, F, Hardy, BW, Murdock, MV, Rush, J.Tridimensional personality questionnaire and serotonin in bulimia nervosa. Psychiatr Res 1993;48: 9–15. CrossRefGoogle ScholarPubMed
Limson, R, Goldman, D, Roy, Aet al. Personality and cerebrospinal fluid monoamine metabolites in alcoholics and controls. Arch Gen Psychiatry 1991;48: 437–441.CrossRefGoogle ScholarPubMed
Nelson, EC, Cloninger, CR.The tridimensional questionnaire as a predictor of response to nefazodone treatment of depression. J Affect Disord 1995;35: 51–57.CrossRefGoogle ScholarPubMed
Gerra, G, Zaimovic, A, Timpano, M, Zambelli, U, Delsignore, R, Brambilla, F.Neuroendocrine correlates of temperament traits in humans. Psychoneuroendocrinol 2000;25: 479–496. CrossRefGoogle ScholarPubMed
Pitchot, W, Ansseau, M, Gonzalez Moreno, Aet al. The flesinoxan 5-HT1A receptor challenge in major depression and suicidal behaviour. Pharmacopsychiatry 1995;28: 91–92.CrossRefGoogle Scholar
Hansenne, M, Pitchot, W, Gonzalez Moreno, A, Reggers, J, Machurot, P-Y, Ansseau, M.Harm avoidance dimension of the tridimensional personality questionnaire (TPQ) and serotonin-1A activity in depressed patients. Biol Psychiatry 1997;10: 959–966. CrossRefGoogle Scholar
Hansenne, M, Pitchot, W, Pinto, E, Kjiri, K, Ajamieh, A, Ansseau, M.Temperament and character inventory (TCI) and depression. J Psychiatr Res 1999;33: 31–36.CrossRefGoogle ScholarPubMed
Chien, AJ, Dunner, DL.The tridimensional personality questionnaire in depression: state versus trait issues. J Psychiatr Res 1996;30: 21–27.CrossRefGoogle ScholarPubMed
Hansenne, M, Ansseau, M.Harm avoidance and serotonin. Biol Psychol 1999;51: 77–81.CrossRefGoogle ScholarPubMed
Ebstein, RP, Gritsenko, I, Nemanov, L, Frisch, A, Osher, Y, Belmaker, RH.No association between the serotonin transporter gene regulatory region polymorphism and the tridimensional personality questionnaire (TPQ) temperament of harm avoidance. Mol Psychiatry 1997;3: 224–226. CrossRefGoogle Scholar
Ricketts, MH, Hamer, RM, Sage, JI, Manowitz, P, Feng, F, Menza, MA.Association of a serotonin transporter gene promoter polymorphism with harm avoidance behaviour in an elderly population. Psychiatr Genet 1998;41: 44. Google Scholar
Blairy, S, Massat, I, Staner, Let al. 5-HT2a receptor polymorphism gene in bipolar disorder and harm avoidance personality trait. Am J Med Genet 2000;96: 360–364.3.0.CO;2-E>CrossRefGoogle ScholarPubMed
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994. Google Scholar
Norden, RJ.Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 1989;13: 885–893.CrossRefGoogle ScholarPubMed
Cornelius, JR, Soloff, PH, Perel, JM, Ulrich, RF.Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 1990;26: 151–154.Google ScholarPubMed
Markovitz, PJ, Calabrese, JR, Schulz, SC, Meltzer, HY.Fluoxetine in the treatment borderline and schizotypal personality disorders. Am J Psychiatry 1991;148: 1064–1067.Google ScholarPubMed
Markovitz, PJ.Pharmacotherapy of impulsivity, agression and related disorders. In: Stein, D, Hollander, E, eds. Impulsive agression and disorders of impulse control. Sussex: Wiley, 1995: 263–287. Google Scholar
Salzman, C, Wolfson, AN, Schatzberg, A.Effect of fluoxetine on anger in symtopmatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995;15: 23–29.DOI: 10.1097/00004714-199502000-00005CrossRefGoogle Scholar
Cocarro, EF, Kavoussi, RJ.Fluoxetine and impulsive agressive behaviour in personality-disordered subjects. Arch Gen Psychiatry 1997;54: 1081–1088.CrossRefGoogle Scholar
Kavoussi, RJ, Liu, J, Cocarro, EF.An open trial of serlatrine in personality disordered patients with impulsive agression. J Clin Pychiatry 1994;55: 137–141. Google Scholar
Markovitz, PJ, Wagner, SC. An open trial of venlafaxine in borderline personality disorder. Presented at the 35th annual meeting of the New Clinical Drug Evaluation Unit: 31 May−3 June, Orlando, 1995. Google Scholar
Verkes, RJ, Pijl, H, Meinders, E, Van Kempen, GMJ.Borderline personality, impulsiveness, and platelet mo,oamine measures in bulimia nervosa and recurrent suicidal behaviour. Biol Psychiatry 1996;40: 173–180.CrossRefGoogle Scholar
Verkes, RJ, Van der Mast, RC, Kerkhof, AJet al. Platelet serotonin, monoamine oxidase activity, and [3H] paroxetine binding related to impulse suicide attemps and borderline personality disorder. Biol Psychiatry 1998;43: 740–746.CrossRefGoogle Scholar
Martial, J, Paris, J, Leyton, Met al. Neuroendocrine study of serotonin function in female borderline personality disorder patients: a pilot study. Biol Psychiatry 1997;42: 737–739.CrossRefGoogle ScholarPubMed
Soloff, PH, Meltzer, CC, Greer, PH, Constantine, D, Kelly, TM.A fenfluramine-activated FDG-PET study of borderline personality disorder. Biol Psychiatry 2000;47: 540–547.CrossRefGoogle Scholar
Hollander, E, Stein, DJ, Decaria, CMet al. Serotonergic sensitivity in borderline personality disorder: preliminary findings. Am J Psychiatry 1994;151: 277–280.Google Scholar
Stein, DJ, Hollander, E, Decaria, CM, Simeon, D, Cohen, L, Aronowitz, B.m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioural response, and clinical measures. Biol Psyciatry 1996;40: 508–513. CrossRefGoogle Scholar
Rinne, T, Westenberg, HGM, Den Boer, JA, Van Der Brink, W.Serotonin blunting to meta-Chlorophenylpiperazine (m-CCP) highly correlates with sustained chilhood abuse in impulsive and antoagressive female borderline patients. Biol Psychiatry 2000;47: 548–556.CrossRefGoogle Scholar
Pitchot, W.Biological bases of suicidal behaviour. neuroendocrine approach of monoamines and HPA axis.Unpublished Thesis. University of Liège, 1996. Google Scholar